Turing Pharmaceuticals Claims “Several” Anti-Toxoplasmosis Candidates in Preclinical Development
In a press release yesterday, Turing Pharmaceuticals—the sole US seller of Daraprim...
-
About Pathophilia
Recent From Pharma
More-
In Alzheimer Phase 3 Development, Yet Another One Bites the Dust
-
US Development (or “Development”) of Benznidazole Reaches a Hitch and It’s All About Money
-
Another Priority Review Voucher (PRV) Sold, This Time for $125 Million
-
More on the Closed Distribution of Daraprim: Should Shkreli Have Really Been “Shocked” by It?
Most recent articles
Kalobios CEO: Martin Shkreli Played Fast and Loose With Early Savant Deal for Benznidazole
Here is a recent BioFlash podcast, in which Kalobios (KBIO) CEO Cameron Durrant provided an update on the...
FDA Approves First Drug for Duchenne Muscular Dystrophy
This morning the FDA announced its approval of eteplirsen (brand name, Exonys 51) for the treatment of...
Clues to the Black Box That Is Turing Pharmaceuticals: The Forbes Interview With its R&D Head
This is a belated examination of an August 24th Forbes interview with the head of R&D at Turing...
Aducanumab: What a Difference 1 Year Makes—Not
The peer-reviewed results of the aducanumab phase 1B study in prodromal and mild AD are now available in...
Ex-General Counsel of Turing Pharmaceuticals: Closed Distribution of Daraprim “Integral” to Blocking Generic Competitor
Before the Senate Committee on Aging, former general counsel and senior business executive of Turing...